Literature DB >> 3535324

Sellar lesions associated with isolated hyperprolactinaemia. Morphological, immunocytochemical, hormonal and clinical results.

M Riedel, J Noldus, W Saeger, D K Lüdecke.   

Abstract

In 204 patients with sellar lesions and isolated hyperprolactinaemia we analysed and compared many different morphological, immunocytochemical, hormonal, and clinical data for a differentiation of primary (Prl produced by a tumour) and secondary (Prl elevation by PIF inhibition) hyperprolactinaemia. We found Prl-positive pituitary adenomas with primary hyperprolactinaemia in 62.7% and a secondary Prl elevation with different alterations in 37.3% (Prl-negative adenomas 28.9%, craniopharyngeomas 5%, and non-tumourous conditions 3.4%). In secondary hyperprolactinaemia the Prl values did not exceed 130 micrograms/l, higher levels indicated Prl-producing adenomas with a high probability. In patients with Prl elevation below 130 micrograms/l the clinical and sometimes the morphological analysis were not sufficient for a differentiation. Here immunocytochemical studies are necessary for a clear classification of hyperprolactinaemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535324     DOI: 10.1530/acta.0.1130196

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  4 in total

1.  MRI of pituitary macroadenomas with reference to hormonal activity.

Authors:  P Lundin; R Nyman; P Burman; P O Lundberg; C Muhr
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

2.  Hypothalamic failure as a sequela of heterozygous protein C deficiency?

Authors:  S Schmitt; K Auberger; T Fendel; W Kiess
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

3.  HGH, PRL and beta HCG/beta LH gene expression in clinically inactive pituitary adenomas detected by in situ hybridization.

Authors:  E Bäz; W Saeger; H Uhlig; S Fehr; D K Lüdecke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 4.  Current management of prolactinomas.

Authors:  P Nomikos; M Buchfelder; R Fahlbusch
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.